I first covered the groundbreaking work of Sanford Burnham’s Dr. Alexey Terskikh in 2015. Two years later, I interviewed Dr. Terskikh with the help of reader questions. It was a lengthy and highly interesting question and answer session. The doctor’s main issue at the time was funding.
A few months ago, Dr. Teskikh provided an excellent update on his hair loss research. Key quote from that interview:
“Instead of embryonic stem cells, which are difficult to obtain, our method now uses induced pluripotent stem cells (iPSC), which are derived from a simple blood draw or skin sample. iPSCs allow us to create an unlimited supply of cells to grow hair. Not having enough hair is one reason current transplants don’t work, so this is a critical advance….We’ve found a solution—3D biodegradable scaffolds—and partnered with leading scientists in the field to advance our project. The scaffold allows us to control the number of cells transplanted, their direction and where they are placed.”
Dr. Terskikh also said that as of 2018, he had formed a company to move this research and technology forward. He did not name the company or the “great team” of experts that he had assembled.
Earlier today, a reader by the name of “Gabriel” sent me the below that was posted on Twitter three weeks ago, but missed by most.
Great breakfast meeting at @EstanciaLaJolla with #hairrestoration surgery colleague Dr Alan J. Bauman from #BocaRaton. Excited to be the medical directors for Stemson Therapeutics, a new biotech company here in #LaJolla developing groundbreaking permanent solutions for #hairloss pic.twitter.com/wTFY6bl5GA
— Dr Richard Chaffoo (@DrChaffoo) October 9, 2018
No mention of Dr. Alexey Terskikh in there, but….
It seems like Stemson Therapeutics LLC was registered in California in 2017 by Dr. Terskikh! Also, Dr. T is based in La Jolla (San Diego), and the Tweet above also mentions La Jolla.
Note that there is also a Stemson Therapeutics Corporation that is involved in the hair growth sector.
This looks like excellent news, even if it may take a few years before fruition.
Unless Trump issues an executive order that Phase 2 and Phase 3 trials are unnecessary :-)
Although, in this case, if the biological material and lab processes are entirely autologous… maybe portions of human trials can be rushed or skipped?